- Home
- CDNA vs AIO Comparison
CDNA vs AIO Comparison
Compare CDNA & AIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDNA
- AIO
- Stock Information
- Founded
- CDNA 1998
- AIO 2019
- Country
- CDNA United States
- AIO United States
- Employees
- CDNA N/A
- AIO N/A
- Industry
- CDNA Medical Specialities
- AIO Finance/Investors Services
- Sector
- CDNA Health Care
- AIO Finance
- Exchange
- CDNA Nasdaq
- AIO Nasdaq
- Market Cap
- CDNA 712.2M
- AIO 808.3M
- IPO Year
- CDNA 2014
- AIO N/A
- Fundamental
- Price
- CDNA $13.53
- AIO $24.36
- Analyst Decision
- CDNA Buy
- AIO
- Analyst Count
- CDNA 8
- AIO 0
- Target Price
- CDNA $26.86
- AIO N/A
- AVG Volume (30 Days)
- CDNA 1.5M
- AIO 141.5K
- Earning Date
- CDNA 11-03-2025
- AIO 01-01-0001
- Dividend Yield
- CDNA N/A
- AIO 9.05%
- EPS Growth
- CDNA N/A
- AIO N/A
- EPS
- CDNA 1.00
- AIO N/A
- Revenue
- CDNA $340,826,000.00
- AIO N/A
- Revenue This Year
- CDNA $13.02
- AIO N/A
- Revenue Next Year
- CDNA $12.85
- AIO N/A
- P/E Ratio
- CDNA $13.56
- AIO N/A
- Revenue Growth
- CDNA 14.72
- AIO N/A
- 52 Week Low
- CDNA $10.96
- AIO $15.09
- 52 Week High
- CDNA $32.97
- AIO $20.25
- Technical
- Relative Strength Index (RSI)
- CDNA 52.36
- AIO 50.53
- Support Level
- CDNA $13.12
- AIO $23.80
- Resistance Level
- CDNA $13.80
- AIO $24.85
- Average True Range (ATR)
- CDNA 0.67
- AIO 0.36
- MACD
- CDNA 0.16
- AIO 0.04
- Stochastic Oscillator
- CDNA 63.39
- AIO 53.33
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.